CooperVision Introduces New Daily Disposable Toric

CooperVision, Inc. has introduced MyDay toric daily disposable contact lenses, which combine the company’s Optimized Toric Lens Geometry for easy fit and stability and Smart Silicone chemistry for optimal oxygen permeability, improved surface wettability, higher water content and lower modulus. The lenses also feature built-in UV protection that filters 85% of UVA and 96% of UVB rays. MyDay toric lenses have a base curve of 8.6mm and a diameter of 14.5mm and are available in sphere powers from plano to -6.00D (0.25D steps), and -6.00 to -10.00D (0.50D steps); plus powers will be available in the future. Available cylinder powers are -0.75D, -1.25D, and -1.75D (in axes of 10°, 20°, 70°, 80°, 90°, 100°, 110°, 160°, 170°, and 180°) and -2.25D (in axes of 10°, 20°, 90°, 160°, 170°, and 180°). For more information, visit PrescribeMyDay.com/Toric.


January is National Glaucoma Awareness Month

Prevent Blindness

Prevent Blindness and other eye health organizations have declared January as National Glaucoma Awareness Month to educate the public on risk factors for glaucoma and treatment options. Glaucoma affects nearly 3 million people ages 40 and older, and the incidence is likely to rise to 4.3 million by 2032 and 5.5 million by 2050, according to the Prevent Blindness report, Future of Vision: Forecasting the Prevalence and Costs of Vision Problems. Prevent Blindness offers a dedicated web page with information for patients who have glaucoma and their caregivers at PreventBlindness.org/Glaucoma, or individuals can call 800.331.2020.

FDA Approves Rhopressa for Lowering IOP

The U.S. Food and Drug Administration has approved Rhopressa (netarsudil 0.02%) Aerie Pharmaceuticals’ eyedrop for lowering of elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension. The once-a-day eyedrop increases the outflow of aqueous humor through the trabecular meshwork. To see the full product label, click here.

New OTC Drop Targets Ocular Redness

The U.S. Food and Drug Administration has approved LUMIFY (brimonidine tartrate 0.025%), Bausch + Lomb’s over-the-counter eyedrop for the treatment of ocular redness. The low dose of brimonidine selectively constricts veins in the eye, making more oxygen available to surrounding tissue. B+L, a wholly-owned subsidiary of Valeant Pharmaceuticals International, Inc., licensed the product from Eye Therapies, Inc. and expects LUMIFY to be available for purchase in major retailers in the second quarter of 2018. Bausch.com.


Leave A Reply